Search Results
May 28, 2026, 14:04 ET Enlit Africa 2026: Huawei, Sahra Altı Afrika için Akıllı Trafo Merkezi Çözümünü Piyasaya Sürdü
content:https://www.prnewswire.com/news-releases/enlit-africa-2026-huawei-sahra-alt-afrika-icin-akll-trafo-merkezi-cozumunu-piyasaya-surdu-302784869.html
More news about: Huawei
May 28, 2026, 10:00 ET Poshmark Partners with LØREN to Release New Song During Exclusive Closet Drop and Interactive Live Shopping Experience
-- Poshmark, the leading fashion marketplace where style comes alive through discovery and community, today announced an exclusive collaboration with alt-rock artist, producer, and DJ, LØREN. Known for his edgy aesthetic and his genre-bending work writing and producing for global superstars like BLACKPINK
More news about: Poshmark
May 27, 2026, 08:00 ET Nuvation Bio to Present New Quality-of-Life Data for IBTROZI® (Taletrectinib) in Patients with ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2026 Annual Meeting
10% Grade 3/4. 85% of patients experienced increased ALT, including 13% Grade 3/4. Fatal liver events occurred in 0.6% of patients. Median time to first onset of AST or ALT elevation was 15 days (range: 3 days to 20.8 months).Increased AST or ALT each led to dose interruption in 7% of patients and
More news about: Nuvation Bio Inc.
May 27, 2026, 07:30 ET Biohaven Reports Positive Clinical Biomarker and Patient Data: First MoDE and TRAP Extracellular Protein Degraders Achieve Deep, Rapid, Selective Lowering of Disease-Driving Antibodies in Graves' Disease and IgA Nephropathy
BHV-1300 and BHV-1400 show a differentiated safety profile with no clinically significant increases in cholesterol, decreases in albumin, or increases in ALT, AST, or bilirubin. Most AEs were mild and self-resolving, there were no drug discontinuations throughout the patient studies, and no serious or severe
More news about: Biohaven Ltd.
May 27, 2026, 07:00 ET Brii Bio Presents Late-Breaking Data from Its Phase 2 ENSURE Study at EASL Congress 2026, Further Supporting the Potential Role of BRII-179 in Achieving Durable Immunological Control of HBV
achieving sustained HBsAg loss through combination therapy demonstrated favorable off-NA outcomes, characterized by infrequent HBV DNA rebound and no ALT elevations.In a separate oral presentation, Dr. Nina Le Bert will report findings from a translational study evaluating immunological responses
More news about: Brii Biosciences Limited
May 27, 2026, 04:00 ET RAVEN2 YENİ "ŞAVAŞ LORDU" SINIFI İLE BÜYÜK FESTİVAL GÜNCELLEMESİNİ BAŞLATIYOR
Lordu, mızrak kullanan bir yakın dövüş sınıfıdır. Savaş alanı komutanı olarak tasarlanan bu sınıf, etkileyici savaş yeteneklerini kullanarak düşmanları alt üst eder ve savaşın gidişatını değiştirir. Şavaş Lordu'nun lansmanını kutlamak amacıyla RAVEN2, oyuncuların Altın kullanarak Sınıf Değiştirme
More news about: Netmarble
May 26, 2026, 08:00 ET Citius Oncology Announces Presentation of LYMPHIR® Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting
medical management.HepatotoxicityLYMPHIR can cause hepatotoxicity. In the pooled safety population, elevated ALT occurred in 70% of patients, with Grade 3 ALT occurring in 22%; elevated AST occurred in 64% of patients, with Grade 3 AST elevation occurring in 9%. For Grade 3 events, median
More news about: Citius Oncology, Inc.
May 21, 2026, 17:17 ET Rigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA2026 Congress
increased alanine aminotransferase (ALT) occurred in 37% of patients, including Grade 3 or 4 in 4.8%. The median time to first onset for increased AST was 15 days (range: 5 days to 2.5 years) and increased ALT was 24 days (range: 7 days to 3.7 years). Monitor AST and ALT prior to initiating GAVRETO, every
More news about: Rigel Pharmaceuticals, Inc.
May 21, 2026, 17:00 ET Lilly to showcase oncology portfolio across tumor types and treatment modalities at the 2026 American Society of Clinical Oncology Annual Meeting
(AST) occurred in 59% of patients, including Grade 3 or 4 events in 11% and increased alanine aminotransferase (ALT) occurred in 55% of patients, including Grade 3 or 4 events in 12%. Monitor ALT and AST prior to initiating Retevmo, every 2 weeks during the first 3 months, then monthly thereafter and as
More news about: Eli Lilly and Company
May 21, 2026, 17:00 ET Boehringer Ingelheim's oncology portfolio shows strong promise across multiple cancers at ASCO 2026
(n=16), HERNEXEOS-related AEs were reported in 87.5% of patients (n=14); the most common treatment-emergent AEs were increased AST (n=6), increased ALT (n=5), and decreased platelet count (n=5).4 In Cohort B (n=16), HERNEXEOS-related AEs were reported in all patients; the most common treatment-emergent
More news about: Boehringer Ingelheim
May 20, 2026, 10:55 ET Global Intellectual Property Economy Market Size to Exceed USD 230.50 Billion by 2031 -- Gaming Monetization Drives Growth as Fortnite and Roblox Generate Billions Through In-Game Purchases | Arizton
ClerkWiproQuestelDennemeyerMaxval GroupIFI Claims Patent ServicesRWS GroupLighthouse IPIamIP PlatformALT LegalUnified PatentsDolceraWhat Key Findings Will Our Research Analysis Reveal?How big
More news about: Arizton Advisory & Intelligence
May 20, 2026, 09:00 ET CITGO Offering New Loyalty Members Relief at the Pump
www.ClubCITGO.com or by scanning QR codes found on promotional signage at participating stations. Registration only takes a few simple steps, including creating an Alt ID (usually a user's phone number)."With prices rising at the pump, there's never been a better time to experience the benefits of the Club CITGO
More news about: CITGO Petroleum Corporation
May 20, 2026, 08:08 ET Eisai Deepens Body of Clinical Evidence for LENVIMA (Lenvatinib) Across Established Indications at ASCO 2026
erythrodysesthesia (11%), nausea (9%), stomatitis (9%), musculoskeletal pain (8%), rash (8%), increased lipase (7%), abdominal pain (6%), vomiting (6%), increased ALT (5%), and increased amylase (5%).In RCC, the most common adverse reactions (≥30%) observed in LENVIMA + everolimus–treated patients were diarrhea
More news about: Eisai Inc.
May 20, 2026, 08:00 ET MetaVia Highlights Peer-Reviewed Publication Supporting the Anti-Fibrotic Potential of Vanoglipel in MASH
President and Chief Executive Officer of MetaVia. "In the trial, patients treated with vanoglipel demonstrated statistically significant reductions in ALT levels, and the serum fibrosis marker TIMP1, along with a positive trend in liver fibrosis as measured by VCTE (-10.2% from the baseline vs. +10.1% for
More news about: MetaVia Inc.
May 18, 2026, 08:00 ET Astellas to Present Data on Long-Term Outcomes and Clinical Use of Its Portfolio Across Disease Stages at ASCO 2026
transaminase [alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST)] levels > 3x ULN occurred in 2.3% of women receiving VEOZAH and 0.9% of women receiving placebo. No elevations in serum total bilirubin (> 2x ULN) occurred. Women with ALT or AST elevations were generally asymptomatic.
More news about: Astellas Pharma Inc.
May 14, 2026, 23:50 ET Xi Jinping und Donald Trump besichtigen gemeinsam Beijinger Himmelstempel
https://www.facebook.com/344488184365580/posts/1433190015495386 Xi sagte, er habe im Jahr 2017 gemeinsam mit Trump den Kaiserpalast an der Beijinger Zentralachse besichtigt. Der Himmelstempel sei genauso alt wie der Kaiserspalast und habe die Symbolik „Der Himmel ist rund und die Erde quadratisch", was die Weltanschauung und die Lebensphilosophie der Chinesen
More news about: CMG
May 13, 2026, 16:05 ET Nuvation Bio to Collaborate with Thermo Fisher Scientific for U.S.-Based Manufacturing of IBTROZI® for ROS1-Positive Non-Small Cell Lung Cancer
Grade 3/4. 85% of patients experienced increased ALT, including 13% Grade 3/4. Fatal liver events occurred in 0.6% of patients. Median time to first onset of AST or ALT elevation was 15 days (range: 3 days to 20.8 months). Increased AST or ALT each led to dose interruption in 7% of patients and
More news about: Nuvation Bio Inc.
May 13, 2026, 08:47 ET Parks Associates Releases Top Ten US FAST Services, with Tubi, The Roku Channel, and Pluto TV Leading
beyond.Goodman will present and share Parks Associates data in back-to-back sessions next week at TVOT (TV of Tomorrow) MONTREAL 2026 at The Alt Hotel, Montreal, Canada. On May 21, he will present on "CTV Advertising I: What's Working, What Isn't, and Why" at 9:55 am and "CTV Advertising II: What's
More news about: Parks Associates
May 12, 2026, 07:00 ET New Altesa BioSciences Data: Vapendavir Demonstrates Anti-Viral Activity Against All Three Rhinovirus Species
clinical, computational, and laboratory research. Using newly developed RV-C culture models, Altesa confirmed that both vapendavir and its active metabolite ALT-001 dose-dependently inhibited RV-C at clinically relevant concentrations. In silico modeling indicated a potential mechanism of direct entry inhibition
More news about: Altesa Biosciences Inc.
May 12, 2026, 07:00 ET Rigel Enters Exclusive Global Licensing Agreement for VEPPANU™ (vepdegestrant), an oral PROTAC, for the Treatment of 2L+ ER+/HER2-, ESR1m Advanced or Metastatic Breast Cancer
abnormalities, were decreased white blood cells, increased AST, musculoskeletal pain, fatigue, decreased hemoglobin, decreased neutrophils, increased ALT, increased alkaline phosphatase, nausea, decreased blood potassium, increased bilirubin, decreased appetite, electrocardiogram QT prolonged, decreased
More news about: Rigel Pharmaceuticals, Inc.
May 08, 2026, 06:35 ET Knight Therapeutics anuncia a aprovação regulatória do TAVALISSE® no Brasil
× 10⁹/L por 12 meses ou mais.1As reações adversas mais frequentes (≥5 %) incluíram diarreia, hipertensão, náusea, tontura, elevação de ALT/AST, infecção respiratória, erupção cutânea, dor abdominal, fadiga, dor torácica e neutropenia.6 As reações adversas graves ao medicamento relatadas
More news about: Knight Therapeutics Inc.
May 08, 2026, 06:35 ET Knight Therapeutics anuncia la aprobación regulatoria de TAVALISSE® en Brasil
durante 12 meses o más.1Las reacciones adversas más frecuentes (≥5 %) incluyeron diarrea, hipertensión, náuseas, mareos, elevación de ALT/AST, infección respiratoria, erupción cutánea, dolor abdominal, fatiga, dolor torácico y neutropenia.6 Las reacciones adversas graves al medicamento
More news about: Knight Therapeutics Inc.
May 07, 2026, 07:00 ET Insmed Reports First-Quarter 2026 Financial Results and Provides Business Update
ElevationsIn ASPEN, there was an increase from baseline in average ALT, AST, and alkaline phosphatase levels at all time points from Week 4 through Week 56 in both BRINSUPRI 10 mg and 25 mg arms compared to placebo. The incidence of ALT >3X upper limit of normal (ULN) was 0%, 1.2%, and 0.9%; the incidence
More news about: Insmed Incorporated
May 06, 2026, 08:00 ET Nuvation Bio Announces FDA Acceptance of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in Advanced ROS1-Positive Non-Small Cell Lung Cancer
10% Grade 3/4. 85% of patients experienced increased ALT, including 13% Grade 3/4. Fatal liver events occurred in 0.6% of patients. Median time to first onset of AST or ALT elevation was 15 days (range: 3 days to 20.8 months).Increased AST or ALT each led to dose interruption in 7% of patients and
More news about: Nuvation Bio Inc.
May 05, 2026, 13:45 ET Hyundai Sponsors BeachLife Festival and Donates $15,000 to Adopt the Arts Foundation
day."On‑Stage Donation Presentation and Key ParticipantsDuring the concert, Hyundai Ambassador, Stryker from iHeartRadio's ALT 98.7 was joined on stage by Brandon Ramirez, director of corporate social responsibility and external relations for Hyundai Motor North America, along
More news about: Hyundai Motor America